title: Antithrombotic drug therapy for IgA nephropathy: a meta analysis of randomized controlled trials.
abstract: BACKGROUND
  Antithrombotic agents, including antiplatelet agents, anticoagulants and thrombolysis agents, have been widely used in the management of immunoglobulin A (IgA) nephropathy in Chinese and Japanese populations. To systematically evaluate the effects of antithrombotic agents for IgA nephropathy.
  
  
  METHODS
  Data sources consisted of MEDLINE, EMBASE, the Cochrane Library, Chinese Biomedical Literature Database (CBM), Chinese Science and Technology Periodicals Databases (CNKI) and Japana Centra Revuo Medicina (http://www.jamas.gr.jp) up to April 5, 2011. The quality of the studies was evaluated from the intention to treat analysis and allocation concealment, as well as by the Jadad method. Meta-analyses were performed on the outcomes of proteinuria and renal function.
  
  
  RESULTS
  Six articles met the predetermined inclusion criteria. Antithrombotic agents showed statistically significant effects on proteinuria (p<0.0001) but not on the protection of renal function (p=0.07). The pooled risk ratio for proteinuria was 0.53, [95% confidence intervals (CI): 0.41-0.68; I(2)=0%] and for renal function it was 0.42 (95% CI 0.17-1.06; I(2)=72%). Subgroup analysis showed that dipyridamole was beneficial for proteinuria (p=0.0003) but had no significant effects on protecting renal function. Urokinase had statistically significant effects both on the reduction of proteinuria (p=0.0005) and protecting renal function (p<0.00001) when compared with the control group.
  
  
  CONCLUSIONS
  Antithrombotic agents had statistically significant effects on the reduction of proteinuria but not on the protection of renal function in patients with IgAN. Urokinase had statistically significant effects both on the reduction of proteinuria and on protecting renal function. Urokinase was shown to be a promising medication and should be investigated further.
authors: Division of Nephrology, 94 Hospital of Chinese PLA, PR China. liuxinfanjian@126.com
authors: Xiu-Juan
authors: XJ
authors: Liu
authors: Yan-Qiu
authors: YQ
authors: Geng
authors: Shao-Nan
authors: SN
authors: Xin
authors: Guo-Ming
authors: GM
authors: Huang
authors: Xiao-Wen
authors: XW
authors: Tu
authors: Zhong-Ru
authors: ZR
authors: Ding
authors: Xiang-Mei
authors: XM
authors: Chen
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000453:epidemiology* / Q000378:metabolism; D006801:Humans; D011507:Proteinuria / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D001552:Benzazepines; D005343:Fibrinolytic Agents; C044946:benazepril